AG真人官方

Quest Diagnostics (DGX) officer Patrick Plewman reported option exercise and a contemporaneous sale on 08/19/2025. He exercised 4,532 non-qualified stock options at an exercise price of $112.17 per share, resulting in ownership of 4,532 underlying shares. Immediately thereafter he sold 4,532 shares at $183.00 per share. After these transactions his beneficial ownership in the issuer is reported as 17,244 shares. The filings state the exercise and sale were executed pursuant to a Rule 10b5-1 sales plan and that the options vested in three annual installments between 2021 and 2023.

Quest Diagnostics insider Thomas P. Plewman filed a Form 144 disclosing a proposed sale of 1,975 common shares (approximate aggregate market value $365,375) to be sold via Fidelity Brokerage Services on the NYSE on 08/21/2025. The shares were acquired on 02/18/2022 upon restricted stock vesting and were received as compensation. The filer also reported three recent sales in August 2025 totaling 12,042 shares for gross proceeds of $2,153,481 (sales on 08/06/2025, 08/15/2025, and 08/19/2025). The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.

Patrick Plewman, Senior Vice President for Diagnostic Services at Quest Diagnostics Inc. (DGX), reported a sale of 1,975 shares of Quest Diagnostics common stock on 08/15/2025 at a price of $180 per share. Following the reported sale, Mr. Plewman beneficially owns 17,244 shares, held directly. The filing notes the sale was effected pursuant to a Rule 10b5-1 sales plan. The Form 4 was executed on behalf of Mr. Plewman by an attorney-in-fact on 08/19/2025.

Form 144 notice for Quest Diagnostics (DGX) shows a proposed sale of 4,532 common shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $829,356.00 and an approximate sale date of 08/19/2025. The shares were acquired on 08/19/2025 under options originally granted 02/18/2020 and payment is indicated as cash. The filer also reported two recent sales by the same person: 5,535 shares on 08/06/2025 for $968,625.00 and 1,975 shares on 08/15/2025 for $355,499.90. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.

Quest Diagnostics (DGX) Form 144 notice shows a proposed sale of 72 shares of common stock through Fidelity Brokerage (approximate aggregate market value $12,960.00) with an approximate date of sale of 08/15/2025. The filer reports prior acquisitions via the company's ESPP: 12 shares acquired 01/31/2022 and 60 shares acquired 07/19/2024, both paid in cash. The filing also discloses a recent sale by Thomas P. Plewman of 5,535 shares on 08/06/2025 for gross proceeds of $968,625.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and references trading-plan/Rule 10b5-1 provisions but does not state a plan adoption date.

The filing reports insider activity by Karthik Kuppusamy, SVP, Clinical Solutions at Quest Diagnostics (DGX). On 08/13/2025 he had a disposition of 123 shares of Quest Diagnostics common stock executed under code F at a price of $175.91 per share; the filer states this sale was made solely to cover tax withholding on vested restricted stock units. Following the reported transaction, Kuppusamy beneficially owned 8,338 shares directly, plus 358 shares indirectly via a trust and 1,628 shares held in the 401(k) plan, with the 401(k) amount provided by the plan administrator based on current account balances.

Quest Diagnostics (DGX) filed a Form 144 reporting a proposed sale of 1,903 common shares through Fidelity Brokerage Services (900 Salem Street, Smithfield, RI) with an approximate aggregate market value of $342,54008/15/2025. The filing lists total shares outstanding as 111,823,441. The document also discloses a recent sale by Thomas P. Plewman of 5,535 common shares on 08/06/2025 for gross proceeds of $968,625. The record of acquisition shows numerous small purchases and vesting events (ESPP purchases, dividend reinvestments, restricted stock vesting) between 02/01/2021 and 06/28/2024 that underlie the holdings to be sold.

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics Inc. (DGX), exercised non-qualified stock options and sold shares under a Rule 10b5-1 plan on 08/06/2025. The filing shows an exercise of 3,560 options at an exercise price of $86.63 and subsequent sales of 3,560 shares at $175 and an additional 1,975 shares at $175. Following these transactions the reporting person beneficially owned 19,219 shares and the reported option grant counts are 0. The filing notes the exercise and sales were effected pursuant to a Rule 10b5-1 sales plan, that the option vested in three annual installments beginning Feb 18, 2020, and that the beneficial ownership total includes exempt purchases under the company stock purchase plan since the last Form 4.